2-Propoxy-4-amino-benzoesaeure | 2486-79-5

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 2-Propoxy-4-amino-benzoesaeure
• 英文别名: 4-amino-2-propoxy-benzoic acid；4-Amino-2-propoxy-benzoesaeure；Benzoic acid, 4-amino-2-propoxy-；4-amino-2-propoxybenzoic acid
• CAS: 2486-79-5
• 化学式: C₁₀H₁₃NO₃
• 分子量: 195.218
• InChiKey: CRLNBJGBAUCAMP-UHFFFAOYSA-N

物化性质

• 熔点：
  180-181 °C (decomp)
• 沸点：
  380.0±27.0 °C(Predicted)
• 密度：
  1.210±0.06 g/cm3(Predicted)
• 溶解度：
  可溶于二甲基亚砜；甲醇；DMF

计算性质

• 辛醇/水分配系数(LogP)：
  1.5
• 重原子数：
  14
• 可旋转键数：
  4
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.3
• 拓扑面积：
  72.6
• 氢给体数：
  2
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  2-Propoxy-4-amino-benzoesaeure 在 硫酸 、 水 、 sodium nitrite 作用下， 反应 4.0h， 生成 4-Hydroxy-2-propoxybenzoic acid
  参考文献：
  名称：

  WO2008/11539

  摘要：

  公开号：
• 作为产物：
  描述：

  methyl 4-(acetylamino)-2-(n-propoxy)benzoate 在 氢氧化钾 作用下， 生成 2-Propoxy-4-amino-benzoesaeure
  参考文献：
  名称：

  Grimme; Schmitz, Chemische Berichte, 1954, vol. 87, p. 179,181

  摘要：

  DOI：

文献信息

• Compounds and their salts specific to the PPAR receptors and the EGF receptors and their use in the medical field
  申请人：Naccari Giancarlo

  公开号：US20090118357A1

  公开（公告）日：2009-05-07

  Therefore the present invention relates specifically to the compounds of general formula (I), in which R 1 and R 2 , which may be identical or different, are selected from the group comprising H, —C n H 2n-1 , a linear or branched alkyl group having from 1 to 6 carbon atoms, or together form an aromatic or aliphatic ring with 5 or 6 atoms; R 3 is selected from —CO—CH 3 , —NHOH, —OH, —OR 6 in which R 6 is a linear or branched alkyl group having from 1 to 6 carbon atoms; R 4 is selected from H, a linear or branched alkyl group having from 1 to 6 carbon atoms, phenyl, benzyl, —CF 3 or —CF 2 CF 3 , vinyl or allyl; R 5 , R 7 , R 8 are hydrogen atoms; or R 3 and R 4 , R 4 and R 5 , or R 7 and R 8 together form a ring, fused to the benzene, aromatic or aliphatic ring with 5 or 6 atoms comprising from 1 to 2 heteroatoms selected independently from the group comprising N, O, and use thereof in the medical field.

  因此，本发明特别涉及具有通用公式（I）的化合物，其中R1和R2，可以相同或不同，选自包括H，—CnH2n-1，具有1到6个碳原子的直链或支链烷基，或者共同形成一个含有5或6个原子的芳香族或脂肪族环；R3选自—CO—CH3，—NHOH，—OH，—OR6，其中R6是一个具有1到6个碳原子的直链或支链烷基；R4选自H，具有1到6个碳原子的直链或支链烷基，苯基，苄基，—CF3或—CF2CF3，乙烯基或烯丙基；R5，R7，R8是氢原子；或者R3和R4，R4和R5，或R7和R8共同形成一个环，与苯环，芳香族或脂肪族环融合，含有5或6个原子，并包括1到2个独立选自N，O的杂原子，及其在医疗领域的应用。
• [EN] METHODS OF TREATING HAIR RELATED CONDITIONS<br/>[FR] PROCÉDÉS DE TRAITEMENT DE TROUBLES LIÉS AU SYSTÈME PILEUX
  申请人：NOGRA PHARMA LTD

  公开号：WO2014041140A1

  公开（公告）日：2014-03-20

  Provided herein are methods for enhancing epidermal regeneration in a patient in need thereof, comprising topically administering to said patient a pharmaceutically acceptable composition comprising N-acetyl- 3-(4-aminophenyl)-2-methoxypropionic acid or a pharmaceutically acceptable salt or stereoisomer thereof, and a pharmaceutically acceptable excipient. For example, provided are methods for treating or ameliorating cicatricial alopecia, comprising topically administering to a patient in need thereof a pharmaceutically acceptable composition comprising the disclosed compounds. Also provided are methods for protecting hair follicle progenitor cells and compositions comprising same using the disclosed compounds.

  本文提供了一种增强患者表皮再生的方法，包括向该患者局部施用含有N-乙酰基-3-(4-氨基苯基)-2-甲氧基丙酸或其药学上可接受的盐或立体异构体和药学上可接受的赋形剂的药学上可接受的组合物。例如，本文提供了治疗或改善瘢痕性脱发的方法，包括向需要该药物的患者局部施用含有上述化合物的药学上可接受的组合物。此外，本文还提供了使用上述化合物保护毛囊祖细胞和含有这些化合物的组合物的方法。
• [EN] METHODS OF INHIBITING HAIR GROWTH<br/>[FR] PROCÉDÉS D'INHIBITION DE LA CROISSANCE PILEUSE
  申请人：NOGRA PHARMA LTD

  公开号：WO2014041141A1

  公开（公告）日：2014-03-20

  Provided herein are methods for reducing mammalian hair growth using the disclosed compounds. Also provided herein are methods of inhibiting hair growth after hair removal of an area of mammalian skin of a mammal using the disclosed compounds.

  本文提供了使用披露的化合物减少哺乳动物毛发生长的方法。本文还提供了使用披露的化合物抑制哺乳动物皮肤区域脱毛后毛发生长的方法。
• Enzymatic method for textile dyeing
  申请人：Novozymes A/S

  公开号：US20010037532A1

  公开（公告）日：2001-11-08

  The present invention relates to methods of dyeing a material which involve contacting the material with a dyeing system which comprises: (a) a mixture of (i) an aromatic diamine and (ii) one or more of a naphthol and an aminonaphthalene and (b) an oxidation system comprising (i) a hydrogen peroxide source and an enzyme exhibiting peroxidase activity or (ii) an enzyme exibiting oxidase activity on one or more of the compounds of mixture (a). The material may be a fabric, yarn, fiber, garment or film made of fur, hide, leather, silk or wool, or made of cationic polysaccharide, cotton, diacetate, flax, linen, lyocel, polyacrylic, synthetic polyamide, polyester, ramie, rayon, triacetate, or viscose.

  本发明涉及一种染色材料的方法，其中涉及将材料与染色系统接触，该染色系统包括：（a）芳香族二胺和萘酚和/或氨基萘之一或多种的混合物；以及（b）氧化系统，其中包括（i）过氧化氢源和表现出过氧化酶活性的酶或（ii）在混合物（a）中的一种或多种化合物上表现出氧化酶活性的酶。该材料可以是毛皮、兽皮、皮革、丝绸或羊毛制成的织物、纱线、纤维、服装或薄膜，或是阳离子多糖、棉、醋酸二乙酯、亚麻、亚麻布、莱赛尔、聚丙烯酸、合成聚酰胺、聚酯、苎麻、人造丝或粘胶制成的织物、纱线、纤维、服装或薄膜。
• Drug evolution: drug design at hot spots
  申请人：Konishi Yasuo

  公开号：US20060110743A1

  公开（公告）日：2006-05-25

  A new method of designing and generating compounds having an increased probability of being drugs, drug candidates, or biologically active compounds, in particular having a therapeutic utility, is disclosed. The method consists of identifying a group of bioactive compounds, preferably of diverse therapeutic uses or biological activities and built on a common building block. In this group of compounds, side chains modifying the building block are identified and used to generate a second set of compounds according to the proposed methods of hybridization”, “single substitution” or “incorporation of frequently used side chains”. If the compounds in the second set built on the same building block contain an unusually large number of drugs, preferably with diverse therapeutic uses or biological activities, they constitute a “hot spot”. A focused combinatorial library of the “hot spot” is then generated, preferably by methods of combinatorial chemistry, and compounds of this library are screened for a variety of therapeutic uses or biological activities. The method generates drugs, drug candidates, or biologically active compounds with a high probability, without requiring any prior knowledge of biological targets.

  本文揭示了一种设计和生成化合物的新方法，这些化合物具有成为药物、药物候选物或生物活性化合物的概率增加，特别是具有治疗效用。该方法包括识别一组生物活性化合物，最好是具有不同治疗用途或生物活性，并建立在共同的基础上。在这组化合物中，识别修改基础结构的侧链，并使用“杂交”、“单一替换”或“纳入常用侧链”的建议方法生成第二组化合物。如果第二组化合物建立在相同的基础结构上，包含异常数量的药物，最好是具有不同治疗用途或生物活性，它们构成一个“热点”。然后通过组合化学的方法生成一个专注的组合式库，其中包括“热点”的化合物，并对该库中的化合物进行各种治疗用途或生物活性的筛选。该方法生成的药物、药物候选物或生物活性化合物具有高概率，无需任何先前的生物靶标知识。